Lentiviral Vector Gene Therapy: Effective and Safe?
Year: 2010
Type: editorial
Abstract: Over the past decade, more than 30 patients with different immunodeficiency disorders have been treated successfully using murine leukemia virus (MLV)-based γ-retroviral vectors to transfer therapeutic genes to autologous hematopoietic cells.1,2,3 However, this approach has been complicated by adverse events caused by γ-retroviral vector integration into the target cell genome. Five cases of lymphoid leukemia have been reported from two different X-linked severe combined immunodeficiency (SCID-X1) trials,4,5 while a recent report now documents two cases of myelodysplasia occurring in a clinical trial for X-linked chronic granulomatous disease.
Source: Molecular Therapy
DOI: 10.1038/mt.2010.70
Author: Derek A Persons
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W2041709256
